Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2010 - 2026)

Sarepta Therapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 26.51% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (down 26.51% YoY), and the FY2025 full-year result was $2.2 billion, down 7.56% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $1.7 billion, down from $2.2 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $2.7 billion in Q4 2022, with the low at $1.7 billion in Q1 2026.
• Average Total Non-Current Liabilities over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities advanced 25.1% in 2022 and declined 26.51% in 2026.
• Tracing SRPT's Total Non-Current Liabilities over 5 years: stood at $2.7 billion in 2022, then fell by 12.54% to $2.4 billion in 2023, then advanced by 0.88% to $2.4 billion in 2024, then retreated by 7.56% to $2.2 billion in 2025, then retreated by 24.25% to $1.7 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.

Peer Comparison